Merck and Pfizer Reports Results of Avelumab in P-III JAVELIN Ovarian 100 study for Previously Untreated Advanced Ovarian Cancer

 Merck and Pfizer Reports Results of Avelumab in P-III JAVELIN Ovarian 100 study for Previously Untreated Advanced Ovarian Cancer

Merck and Pfizer Reports Results of Avelumab in P-III JAVELIN Ovarian 100 study for Previously Untreated Advanced Ovarian Cancer

Shots:
  • The P-III JAVELIN Ovarian 100 study involves assessing of avelumab + and/or following Pt-based carboplatin/paclitaxel CT in 998 patients with LA or metastatic (Stage III or Stage IV) epithelial ovarian cancer, fallopian tube cancer (FTC), or primary peritoneal cancer
  • The study resulted in unmet 1EPs as PFS and has shown no new safety signals with
    consistent safety profile
  • Avelumab is anti-programmed death ligand-1 (PD-L1) Ab that blocks its interaction with PD-L1
    with PD-1 receptors. In, 2014 Merck and Pfizer collaborates to co-develop and co-commercialize avelumab

Click here to read full press release/ article | Ref: Pfizer | Image: Buzzercast

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post